RELMADA THERAPEUTICS

Company snapshot

Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations. Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance seprano

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for RELMADA THERAPEUTICS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for RELMADA THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   NDV01 intravesical controlled release formulation of gemcitabine and docetaxel — Phase 2

2. Jun 8, 2026 Clinical update

   NDV-01 (sustained-release gemcitabine-docetaxel) — Phase 3

3. Jun 8, 2026 Clinical update

   NDV-01 (sustained-release gemcitabine-docetaxel) — Phase 3

4. May 23, 2026 Clinical update

   REL-1017 — Phase 3

5. May 23, 2026 Clinical update

   REL-1017 — Phase 2

View all clinical trial activity →

• What is RELMADA THERAPEUTICS?

  RELMADA THERAPEUTICS is a pharma organization headquartered in Coral Gables, USA. It trades on NYSE under ticker RLMD. Primary therapeutic focus areas include Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

• Is RELMADA THERAPEUTICS publicly traded?

  Yes. RELMADA THERAPEUTICS is listed with ticker RLMD on NYSE per SEC EDGAR records linked on this profile.

• What drugs does RELMADA THERAPEUTICS develop or market?

  We link 5 drug profile(s) where RELMADA THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/relmada-therapeutics-inc#company-drugs.

• What are the latest developments for RELMADA THERAPEUTICS?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does RELMADA THERAPEUTICS focus on?

  RELMADA THERAPEUTICS focuses on Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Non Muscle Invasive Bladder Cancer based on our analysis of their pipeline programs and drug development activities.